← Leaderboards
Carl Wild
Dfh Pharma, Inc.
$2,287,827
Attributed
$2,287,827
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $986.9K · FY2013–25$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,287,827 · 4
By mechanism
R44$986,894 · 1
R42$943,084 · 1
R41$357,849 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusVirus ReplicationToxic EffectViral Load ResultProtease InhibitorProtein PrecursorsResistanceSp1 GenePharmaceutical PreparationsViralHiv TherapyGenerationsCapsidGag Gene ProductsAmino AcidsExhibitsSeriesHiv-1Genetic PolymorphismNext GenerationParticlePeptide HydrolasesDrug DevelopmentInhibitor/Antagonist
Grant awards (5)
IND-Enabling Development of HIV Maturation Inhibitors Formulated for use as either Oral or Long-Acting Parenterally Administered Agents$986,894
R44 · FY2025 · AI · contact PI
Preclinical Development of 2nd Generation HIV Maturation Inhibitors$424,376
R42 · FY2021 · AI · contact PI
Preclinical Development of 2nd Generation HIV Maturation Inhibitors$518,708
R42 · FY2020 · AI · contact PI
Preclinical Development of 2nd Generation HIV Maturation Inhibitors$171,475
R41 · FY2018 · GM · contact PI
Preparation and Characterization of 2nd Generation HIV-1 Maturation Inhibitor Dru$186,374
R41 · FY2013 · AI · contact PI